Bionure Targets Trophic Signaling For Multiple Sclerosis
By NEUROTECH INSIGHTS. MARCH 1, 2014.
Bionure is a preclinical stage company developing a novel cure for multiple sclerosis. Based in Palo Alto, with offices in Barcelona and San Jose, Bionure began in 2009 and operates as a virtual biotech company with six full-time employees. Neurotech Insights spoke with Albert G. Zamora, CEO.
Their small molecule, BN201, is a new chemical entity with a novel, still confidential, mechanism of action that targets and activates the trophic signaling pathway downstream, avoiding external receptors. The downstream effects result in neuroprotection, and the company is optimistic, could trigger regeneration of myelin. The pre-clinical work is mostly complete. Bionure is wrapping up their regulatory toxicity and formulation experiments. Their candidate molecule has demonstrated solid efficacy in animal models of MS, Optic Neuritis, and glaucoma, including effective blood-brain-barrier crossing. The company has also completed safety trials studies successfully, and has a GMP plan in place for scaled manufacturing, with drug synthesis challenges addressed.
Bionure’s to-market strategy is one that leverages lean startup principles to reach proof-of-concept, and other clinical value inflection points, as quickly and cost-effectively as possible, to address concerns of risk management from the investment community, and accelerate treatment to neurodegeneration patients.